Viral Vector Services

Experience

• With a strong track record in viral vector manufacturing, we offer 20+ years of experience developing processes and producing cGMP viral vectors: AAV, Adenovirus, Lentivirus, HSV, VSV, VEEV and Retrovirus
• We’ve produced 60+ viral vector products and 250+ cGMP clinical or commercial batches using a variety of manufacturing technologies.

Solutions

• Patheon pharma services offers a fully integrated solution for viral vector manufacturing, with a global network of locations to serve your need for development and commercial capabilities. Locations include:
  • Alachua, FL, USA
  • Cambridge, MA, USA
  • Gosselies, Belgium
  • Lexington, MA, USA
  • Plainville, MA, USA
  • Seneffe, Belgium
• Our deep technical and analytical expertise overcome challenges associated with these complex products.
• Single-use equipment allows maximum flexibility for manufacturing platform, scale and project scheduling while ensuring product quality.

Capabilities and Capacity

• Continued global expansion of our cGMP-compliant, state-of-the-art, multi-product facilities ensures the support our clients without long queues.
• Our 1150+ innovative employees are focused on serving the needs of clients and their patients.

Quality

• Quality is at the core of everything we do and we’ve earned the trust of clients around the world.
• Our Quality Management System is specifically designed to ensure regulatory compliance and the highest product quality possible.

An Extension of Your Team

• Our collaborative approach keeps clients involved, engaged and well-informed as we strive to exceed their expectations.
• We operate with transparency and flexibility because every client is unique and each patient matters.

Patient-Focused

• We enable emerging biotech and large pharma customers to deliver breakthrough medicines to patients by unleashing the potential of cell and gene therapy.
• We are uniquely positioned to partner with our clients to drive the innovation in this incredibly fast-growing market to reach even more patients and treat even more indications.